Addressing food allergies—leading an emerging therapeutic space by responding to a growing and critical unmet medical need

The experienced biotech and pharmaceutical leaders of Aimmune’s executive and management teams are inspired by the patients, families and physicians managing the daily risks associated with food allergies.

Executive Team

  • Daniel C. Adelman
    Daniel C. Adelman Chief Medical Officer

    Daniel C. Adelman, MD, is Aimmunes’s Chief Medical Officer. As an allergist and immunologist, he has led drug development at biotechnology companies for more than 20 years and taught and practiced medicine at the University of California, San Francisco, for more than 25 years. Most recently, Dr. Adelman spent seven years as Chief Medical Officer and Senior Vice President of Development at Alvine Pharmaceuticals, a biopharmaceutical company focused on autoimmune and inflammatory diseases, particularly celiac disease. He held the same positions, as Chief Medical Officer and Senior Vice President of Development, during five years at Sunesis Pharmaceuticals, Inc. Earlier, Dr. Adelman served in various roles at Pharmacyclics, Inc., including Vice President of Clinical Operations and Biometrics, and was a Clinical Scientist at Genentech, Inc.

    Dr. Adelman has published extensively in allergy, clinical immunology and autoimmunity, and oncology. He served on the Research Advisory Board of Food Allergy Research & Education (FARE) for more than five years and on the editorial board of the Journal of Allergy and Clinical Immunology for five years. He now serves on several clinical scientific advisory boards and on the editorial boards of Clinical Immunology and Journal of Clinical Immunology. Dr. Adelman holds a bachelor’s degree in biology from the University of California, Berkeley, and earned his MD from the University of California, Davis.

  • Sue Barrowcliffe
    Sue Barrowcliffe General Manager of Europe

    Sue Barrowcliffe is Aimmune’s General Manager of Europe and was formerly the company’s Senior Vice President, Regulatory, as well. She has 25 years of experience in global regulatory affairs and drug development with both large and small companies and has been CEO of a university spun-out oncology research company in the United Kingdom. Most recently, Ms. Barrowcliffe led her own consultancy, Right Track Regulatory, serving biotech companies for more than eight years.

    Previously, she was Director of Regulatory and Medical Strategy for Idis and VP of Regulatory Affairs Europe for Chiron BioPharmaceuticals. She was also VP Development for British Biotech, VP of Worldwide Product Registration for SmithKline Beecham, and Director of European Regulatory Affairs for Marion Merrell Dow. Ms. Barrowcliffe has a first class honours degree in Biochemistry from the University of Sheffield, UK.

  • Ken Boehm
    Ken Boehm SVP, Human Resources

    Ken Boehm is Aimmune’s Senior Vice President of Human Resources. He has more than thirty years of experience in human resources across several industries, including biotech, high-tech, and software, and has led human resources or filled a significant HR role in both very large companies and early stage, start-up companies. Most recently, Mr. Boehm was Senior Vice President, Human Resources, at E2open, a software cloud platform company.

    He was also led human resources for CV Therapeutics, where he was instrumental in their fast growth to nearly one thousand employees as the company prepared for commercial launch. Earlier, he provided human resources leadership at such companies as Gilead, Polycom, and Synopsys. Mr. Boehm holds a BA in Mathematics from the University of California, Los Angeles and an MBA from Pepperdine University.

  • Warren DeSouza
    Warren DeSouza Chief Financial Officer

    Warren DeSouza is Aimmune’s Chief Financial Officer. Mr. DeSouza has 25 years of combined experience in biotechnology finance and audit-assurance consulting. He was most recently Vice President, Finance, at Onyx Pharmaceuticals. In nine years with Onyx, he led accounting, SEC reporting, purchasing, tax, treasury, and risk management, among other responsibilities.

    Prior to Onyx, Mr. DeSouza held a senior role in assurance at Deloitte & Touche LLP. Mr. DeSouza began his career with more than a decade in assurance at Arthur Andersen LLP, where he managed client accounts, led audits and oversaw SEC filings. Mr. DeSouza earned a bachelor’s of Business Administration degree from the University of Notre Dame.

  • Stephen G. Dilly
    Stephen G. Dilly Chief Executive Officer

    Stephen G. Dilly, MBBS, PhD, is Aimmune’s Chief Executive Officer and a member of Aimmune’s Board of Directors. His previous positions include Chief Executive Officer at APT Pharmaceuticals; Senior Vice President, Head of Development, and Chief Medical Officer at Chiron BioPharmaceuticals; and a number of senior executive clinical, development and commercial support positions at Genentech and SmithKline Beecham.

    Dr. Dilly played important roles in the development and approval of numerous drugs, including Kytril®, Requip®, Kredex®, Paxil CR®, Cathflo Activase®, Raptiva®, Xolair®, Avastin®, Lucentis®, Cubicin® and Tarceva®. He is on the Board of Sangamo Biosciences. Dr. Dilly received a PhD in Cardiac Physiology from the University of London and holds an MBBS, graduating as a physician from the University of London.

  • Jeffrey H. Knapp
    Jeffrey H. Knapp Chief Operating Officer

    Jeffrey H. Knapp is Aimmune’s Chief Operating Officer. He brings more than 25 years of experience in the pharmaceutical and biotechnology industry, most recently as Chief Operating Officer at Adamas Pharmaceuticals, which he joined as Chief Commercial Officer in early 2014. Mr. Knapp was previously Chief Commercial Officer at Affymax Inc., where, over seven years in the role, he built out the company’s U.S. commercial organization and led the launch of its first product.

    He has also led sales and marketing at Abgenix, Pharmion, and EMD Pharmaceuticals. He spent the first half of his career at Eli Lilly & Company and Schering-Plough in various sales, marketing and business development roles. Mr. Knapp earned his bachelor’s degree in biology from Wittenberg University.

  • Mary Rozenman
    Mary Rozenman SVP, Corporate Development and Strategy

    Mary Rozenman, PhD, is Aimmune’s Senior Vice President of Corporate Development and Strategy. Prior to joining Aimmune in 2015, Dr. Rozenman was a Vice President at Longitude Capital, where she focused on mid-stage biotechnology investments and was an observer on Aimmune’s Board of Directors. Dr. Rozenman was previously a Junior Partner at McKinsey & Company and a leader in the Healthcare and Corporate Finance practices.

    At McKinsey, she advised senior management of leading pharmaceutical companies on a range of strategic and operational issues across marketing, sales, and clinical and corporate development. She also led McKinsey’s global Biosimilars practice. Dr. Rozenman holds a PhD in Organic Chemistry and Chemical Biology from Harvard University and a BA in Russian Literature and Biochemistry from Columbia University. Her scientific work has been published in premier scientific journals, including Nature, and she is a named inventor on several patents.

  • Douglas Sheehy
    Douglas Sheehy General Counsel and Secretary

    Douglas Sheehy is Aimmune’s General Counsel and Secretary. He has more than 20 years of both in-house and law firm experience, including nearly a decade as general counsel. Mr. Sheehy joined Aimmune from Codexis, Inc., a developer of biocatalysts for the pharmaceutical and fine chemical industries, where he was hired as General Counsel and Secretary in 2007. Most recently, he was also the company’s Chief Administrative Officer.

    Previously, Mr. Sheehy spent five years in key legal roles at CV Therapeutics, Inc., a publicly held biopharmaceutical company that was subsequently acquired by Gilead in 2009. He began his legal career as a corporate attorney at Gunderson Dettmer LLP. Mr. Sheehy holds a BA in history from Dartmouth College and a JD from American University, where he served as Editor-in-Chief of the Law Review.

  • William Turner
    William Turner SVP, Global Regulatory Affairs and Quality Assurance

    Bill Turner is Aimmune’s Senior Vice President, Global Regulatory Affairs and Quality Assurance. He has more than 25 years of experience in regulatory affairs and quality assurance with biotechnology companies in all stages of clinical development, including extensive experience in biologics. Most recently, he led his own consultancy, where he advised executives and led regulatory and quality activities across multiple therapeutic areas.

    Previously, Mr. Turner spent seven years at Dynavax Technologies, where he was Vice President, Regulatory Affairs and Corporate Quality Systems, and six years at MedImmune where he was Senior Director of Regulatory Affairs. Earlier in his career, he handled regulatory affairs at Allergan and Alpha Therapeutics Corporation (now Grifols Biologicals). Mr. Turner holds a BS degree in Medical Microbiology from California State University, Long Beach.

Management Team

  • Laura Hansen
    Laura Hansen VP, Investor Relations

    Laura Hansen, PhD, is Aimmune’s Vice President of Investor Relations. Dr. Hansen has more than 16 years of investor relations and corporate communications experience in the biotechnology industry and has worked with a variety of publicly traded and privately owned companies at various stages in clinical development. Most recently, Dr. Hansen was Senior Director of Corporate Communications at Threshold Pharmaceuticals, Inc.

    Prior to that, she held similar positions in communications at FibroGen, Inc., and Corvas International. She began her communications career on the agency side at Susan E. Atkins & Associates. Dr. Hansen holds a PhD in Biological Sciences and a BS in Zoology from the University of Texas at Austin.

  • Mike Holfinger
    Mike Holfinger VP, Manufacturing and Supply Chain

    Mike Holfinger, PhD, is Aimmune’s Vice President of Manufacturing and Supply Chain. Dr. Holfinger has more than two decades of experience in process development and global manufacturing of commercial products. Most recently, he was Vice President, Manufacturing and Global Supply Chain Management, at Alexza Pharmaceuticals.

    He was previously Vice President, Manufacturing and CMC Development, at Affymax, and he spent 14 years in Manufacturing and Chemical Process Research & Development at Pfizer, Pharmacia and Upjohn. Dr. Holfinger earned his PhD in Chemical Engineering from the University of Wisconsin-Madison and received dual BS degrees in Applied Science and Chemistry at Miami University.

  • Paul Ledger
    Paul Ledger VP, Commercial Operations, Europe

    Paul Ledger is Aimmune’s Vice President of Commercial Operations for Europe and has nearly 20 years of experience in pharmaceutical and medical device commercialization in Europe. Mr. Ledger joined Aimmune from Santhera Pharmaceuticals, where he was Managing Director for the United Kingdom and Nordics. Previously, at GlaxoSmithKline, he was the Global Commercial Head for a number of therapeutic areas in the GSK rare disease group. He also held positions of increasing responsibility during six years at Alexion Pharmaceuticals, first in the commercial area and then as General Manager for the Middle East and Africa.

    Earlier in his career, he held sales and product management positions at Medtronic and Eli Lilly and Company, following his first role in sales at Novartis. Prior to his work in the pharmaceutical industry, Mr. Ledger spent six years in British military intelligence and four years as a head coach and swimming development officer in Sunderland, England. He holds a bachelor’s degree in Sports Science from the University of Sunderland.

  • Annette Marcantonio
    Annette Marcantonio VP, Clinical Operations

    Annette Marcantonio is Aimmune’s Vice President, Clinical Operations. Annette has more than 25 years of global experience in therapeutic product development within the biotechnology, pharmaceutical, and drug-device combination industries, spanning all stages from product development to regulatory filings to post-marketing surveillance. She has deep experience developing and facilitating clinical research collaborations with federal agencies, academic centers and contract research organizations. She has also contributed to clinical-regulatory

    strategies and is a co-author on multiple peer-reviewed publications. Most recently, Ms. Marcantonio spent six years as Head of Clinical Operations at Alvine Pharmaceuticals, a biopharmaceutical company focused on celiac disease. Previously, at both Nektar Pharmaceuticals and Oculex Pharmaceuticals, she held similar leadership positions and built out global infrastructure to support each company’s clinical research needs. Ms. Marcantonio holds an MBA and earned her bachelor’s degree in biology from Loyola Marymount University.

  • Alison Marquiss
    Alison Marquiss VP, Community and Public Affairs

    Alison Marquiss is Aimmune’s Vice President of Community and Public Affairs.  She has nearly 20 years of communications experience in healthcare, technology and environmental policy.  Most recently, as a consultant, she provided primary strategic communications guidance to clinical-stage biotechnology companies.

    Previously, Ms. Marquiss was Director of Global Communications for Novartis Vaccines and Director of Corporate Communications for Chiron Corporation, where she led global communications throughout a period of intense media scrutiny around seasonal and pandemic influenza, vaccines shortages, manufacturing issues, government investigations, and corporate acquisition. She has also co-authored business books on entrepreneurship and biotech investing and reported on local news for print and broadcast.  Ms. Marquiss earned a BA in English from the University of California, Berkeley.

  • Le-Van Nguyen
    Le-Van Nguyen VP, U.S. Regulatory Affairs

    Le-Van Nguyen is Aimmune’s Vice President of U.S. Regulatory Affairs. She has more than 20 years of experience in regulatory affairs, covering a wide range of activities from pre-IND to post-licensure phases across several therapeutic areas. Before joining Aimmune, Ms. Nguyen founded a regulatory affairs consultancy business, where she provided guidance and leadership to multi-disciplinary drug development teams in large and small companies.

    Previously, Ms. Nguyen served as Senior Director, Regulatory Affairs for various biotech companies, including InterMune, APT Pharmaceuticals, CoMentis and Telik. She also held regulatory positions at Millennium Pharmaceuticals (COR Therapeutics), Baxter BioScience, Genelabs Technologies and Scios (Johnson & Johnson). Ms. Nguyen earned a BSc degree in Chemistry from California State University, Fresno.

  • Amr Radwan
    Amr Radwan VP, Medical Affairs and Market Access

    Amr Radwan, MA, MB BChir, is Aimmune’s Vice President of Medical Affairs and Market Access. He was a practicing surgeon and cardiologist in the United Kingdom for nearly 10 years before he joined the pharmaceutical industry in 2006 and applied his expertise to drug safety, risk management, clinical development, and medical affairs. Most recently, Dr. Radwan was Medical Director for Europe at Norgine, where he oversaw market access strategies, pricing and reimbursement applications, and pharmacovigilance activities, among other responsibilities.

    During several years with Novartis, he was Head of Primary Care Therapy, covering a diverse portfolio of primary care and specialist products (including those for allergy), and held other positions in respiratory and pharmacovigilance as well. Dr. Radwan earned his Bachelor of Medicine and Surgery and his MA at the University of Cambridge and is a Member of Faculty of Pharmaceutical Medicine of the Royal College of Physicians.